What BPC-157 actually is

BPC-157 (Body Protection Compound) is a synthetic peptide sequence derived from a protein discovered in human gastric juice. Sikiric and colleagues at the University of Zagreb have published extensively on its accelerating effects in tendon-to-bone healing, ligament repair, muscle tear recovery, and gastrointestinal wound models.¹

Mechanistically, BPC-157 appears to upregulate VEGF (angiogenesis), accelerate fibroblast migration, modulate nitric oxide signaling, and protect endothelium under stress.² Human clinical data remains limited but the preclinical literature is one of the most comprehensive in peptide pharmacology.

At Luxbae, BPC-157 is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Angiogenesis and matrix repair

Upregulates VEGF, accelerates fibroblast migration, modulates NO signaling, protects endothelial integrity under stress.²

What the research shows

Tendon-to-bone healing. Accelerated healing in rat Achilles tendon transection models.¹

Ligament repair. Faster matrix remodeling and tensile-strength recovery in injury models.

Gut barrier. Protective effects in models of NSAID injury, IBD, and gastric ulcer.³

Side effects: Generally well-tolerated. Mild injection-site reactions, transient warmth, occasional headache.

FDA note: BPC-157 is not FDA-approved. Considered investigational; prescribed at Luxbae under physician supervision.

BPC-157 FAQ

How fast does it work?
Many patients report improvement in soft-tissue symptoms within 2–4 weeks of consistent dosing.

Injection near injury?
Common practice — proximity to the affected tissue is preferred when accessible.

References

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2010;16(10):1224-1234.
2. Hsieh MJ, Liu HT, Wang CN, et al. BPC 157 promotes angiogenesis. J Cell Physiol. 2017.
3. Sikiric P, Seiwerth S, Rucman R, et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. 2018.